


ABSTRACT OF THE DISCLOSURE

This invention provides compounds defined by Formula I



I

5 or a pharmaceutically acceptable salt thereof,
wherein R¹, Q, Y³, Y⁴, U⁵, U⁶, U⁸, R², and R³ are as defined in the
specification. The invention also provides pharmaceutical compositions
comprising a compound of Formula I, or a pharmaceutically acceptable salt
thereof, as defined in the specification, together with a pharmaceutically
10 acceptable carrier, diluent, or excipient. The invention also provides methods of
inhibiting an MMP-13 enzyme in an animal, comprising administering to the
animal a compound of Formula I, or a pharmaceutically acceptable salt thereof.
The invention also provides methods of treating a disease mediated by an MMP-
13 enzyme in a patient, comprising administering to the patient a compound of
15 Formula I, or a pharmaceutically acceptable salt thereof, either alone or in a
pharmaceutical composition. The invention also provides methods of treating
diseases such as heart disease, multiple sclerosis, osteo- and rheumatoid arthritis,
arthritis other than osteo- or rheumatoid arthritis, cardiac insufficiency,
inflammatory bowel disease, heart failure, age-related macular degeneration,
20 chronic obstructive pulmonary disease, asthma, periodontal diseases, psoriasis,
atherosclerosis, and osteoporosis in a patient, comprising administering to the
patient a compound of Formula I, or a pharmaceutically acceptable salt thereof,
either alone or in a pharmaceutical composition. The invention also provides
combinations, comprising a compound of Formula I, or a pharmaceutically
25 acceptable salt thereof, together with another pharmaceutically active component
as described in the specification.